Categories
Market & Economy News

Bristol Myers Says U.S. FDA Extends Review of Heart Disease Drug

Drugmaker Bristol Myers Squibb said on Friday the U.S. Food and Drug Administration (FDA) has extended the review of its drug candidate, mavacamten, for the treatment of a heart condition. Read More